
NexEos Diagnostics, Inc., a Pennsylvania-based medical firm, innovates diagnostic tools for chronic, eosinophil-related diseases.
NexEos Diagnostics, Inc., founded in Pottstown, Pennsylvania, is a privately held medical diagnostics company focused on improving the diagnosis, management, and treatment of chronic, eosinophil-related inflammatory diseases. The company's core mission is to develop and commercialize novel technologies that address the unmet needs of patients suffering from these conditions. Their lead product is a rapid, non-invasive imaging agent designed for the diagnosis and monitoring of Eosinophilic Esophagitis (EoE).
Notable affiliated individuals and investors have not been disclosed, but the company has achieved significant milestones in advancing its lead program. NexEos Diagnostics' innovative approach has the potential to significantly impact patient care by providing better diagnostic tools and improving disease management. Their work aims to bring new hope to patients with eosinophil-related diseases, making a meaningful difference in their quality of life.
NX Pharmagen
nxpharmagen.com

Lucid Diagnostics
luciddx.com

Eclipse Diagnostics

Test Diagnostics

Celestia Diagnostics

Exagen
exagen.com

Evanostics
evanostics.com

Precision Theranostics

NX Prenatal
nxprenatal.com

FYR Diagnostics
fyrdiagnostics.com

NOWDiagnostics
nowdx.com

Epinex Diagnostics
epinex.com

Optimum Imaging Diagnostics
optimumidx.com

Nexosome Oncology
Exactus
exactusinc.com

IES Diagnostics
iesdiagnostics.com

Pediatric Bioscience

Pearl Diagnostics
pearldx.com

Neodiagnostix
neodiagnostix.com

Quadrant Biosciences
Companies similar to NexEos Bio include NX Pharmagen, Lucid Diagnostics, Eclipse Diagnostics and Test Diagnostics.
NexEos Bio was founded in 2019.
NexEos Bio's headquarters is located in Chester Springs, PA, US.
NexEos Bio's most recent funding round was for $5.1M (USD) in February 2023.
As of Feb 15, 2023, NexEos Bio has disclosed funding of $17.8M (USD).
NexEos Bio has 30 employees as of Feb 5, 2024.